Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Leuven – page 30

1 129 clinical trials in Leuven, Belgium across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Leuven at a glance
1 129
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 129 trials in Leuven

Open in trial search

Chronic lymphocytic leukaemia

Recruiting

Study Comparing Pirtobrutinib and Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Plasma cell myeloma

Recruiting

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

IgA nephropathy

Recruiting

Long-Term Safety Study of Iptacopan for Adults with IgA Nephropathy After Completing a Previous Study, Including ACE Inhibitors and ARBs Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Congenital cystic kidney disease

Recruiting

Study on the Safety and Effects of Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Tolvaptan
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Neoplasm

Recruiting

Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Relapsing multiple sclerosis+2

Recruiting

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Chronic lymphocytic leukaemia+1

Recruiting

Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Ascentage Pharma Group Inc.

Penile cancer

Recruiting

Study on the Effectiveness of Carboplatin, Paclitaxel, and Pembrolizumab for Patients with Advanced Penile Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Ovarian cancer

Recruiting

Study Comparing Avutometinib and Defactinib with Other Treatments for Patients with Recurrent Low-Grade Serous Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Verastem Inc.

Nephroblastoma

Recruiting

Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

Recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Intellia Therapeutics Inc.

Adenocarcinoma gastric+4

Recruiting

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Boehringer Ingelheim International GmbH

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Leuven

What the registry says about research in the country

01 Gastrointestinal Research

Clinical investigations focusing on ulcerative colitis and innovative treatments for inflammatory bowel conditions. Studies include evaluation of novel therapies for short bowel syndrome and gastrointestinal motility disorders.

  • Inflammatory Bowel Disease Treatment
  • Gastrointestinal Motility Studies
  • Metabolic Disease Research

Current trials are examining drug absorption and therapeutic responses in patients with various digestive conditions.

02 Oncology Studies

Groundbreaking research in head and neck cancer treatments, including innovative radiotherapy approaches. Studies are also investigating new therapies for bladder cancer, focusing on early-stage interventions.

  • Advanced Cancer Therapies
  • Immunotherapy Research
  • Non-invasive Treatment Approaches

Emphasis on combining traditional treatments with novel therapeutic approaches to improve patient outcomes.

03 Neurological Disorders

Comprehensive studies on Alzheimer's disease and frontotemporal dementia, investigating disease progression and potential treatments. Research includes innovative approaches to understanding brain circuit functionality.

  • Cognitive Function Studies
  • Neurodegenerative Disease Research
  • Brain Imaging Technologies

Advanced imaging techniques are being utilized to track disease progression and treatment effectiveness.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.